APO Research
Talk to an analyst

APO RESEARCH · REPORT

Poxviridae Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Poxviridae Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025193 pages

Choose your research edition.

Industry ResearchPoxviridae Infections Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Poxviridae Infections Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Poxviridae Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Poxviridae Infections Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Poxviridae Infections Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Poxviridae Infections Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Poxviridae Infections Drug include Takeda Pharmaceutical Company Limited, China Biologic Products, Inc., Verrica Pharmaceuticals Inc., Tonix Pharmaceuticals Holding Corp., SIGA Technologies, Inc., N & N Pharmaceuticals Inc., EpiVax, Inc., CJ HealthCare Corp. and Chimerix, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Poxviridae Infections Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Poxviridae Infections Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Poxviridae Infections Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Poxviridae Infections Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Poxviridae Infections Drug Segment by Company

Takeda Pharmaceutical Company Limited

China Biologic Products, Inc.

Verrica Pharmaceuticals Inc.

Tonix Pharmaceuticals Holding Corp.

SIGA Technologies, Inc.

N & N Pharmaceuticals Inc.

EpiVax, Inc.

CJ HealthCare Corp.

Chimerix, Inc.

CEL-SCI Corporation

BioFactura, Inc.

Bavarian Nordic A/S

Poxviridae Infections Drug Segment by Type

CJ-40011

BA-368

24a

Others

Poxviridae Infections Drug Segment by Application

Hospital

Clinic

Others

Poxviridae Infections Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Poxviridae Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Poxviridae Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Poxviridae Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Poxviridae Infections Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Poxviridae Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Poxviridae Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Poxviridae Infections Drug Industry Trends Table 2. Poxviridae Infections Drug Industry Drivers Table 3. Poxviridae Infections Drug Industry Opportunities and Challenges Table 4. Poxviridae Infections Drug Industry Restraints Table 5. Global Poxviridae Infections Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Poxviridae Infections Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Poxviridae Infections Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Poxviridae Infections Drug Sales Market Share by Manufacturers Table 9. Global Poxviridae Infections Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Poxviridae Infections Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Poxviridae Infections Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Poxviridae Infections Drug Manufacturers, Product Type & Application Table 13. Global Poxviridae Infections Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Poxviridae Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CJ-40011 Table 17. Major Manufacturers of BA-368 Table 18. Major Manufacturers of 24a Table 19. Major Manufacturers of Others Table 20. Global Poxviridae Infections Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 22. Global Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 23. Global Poxviridae Infections Drug Sales Market Share by Type (2021-2026) Table 24. Global Poxviridae Infections Drug Sales Market Share by Type (2027-2032) Table 25. Global Poxviridae Infections Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Poxviridae Infections Drug Revenue by Type (2021-2026) & (K Units) Table 27. Global Poxviridae Infections Drug Revenue by Type (2027-2032) & (K Units) Table 28. Global Poxviridae Infections Drug Revenue Market Share by Type (2021-2026) Table 29. Global Poxviridae Infections Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Poxviridae Infections Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 35. Global Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 36. Global Poxviridae Infections Drug Sales Market Share by Application (2021-2026) Table 37. Global Poxviridae Infections Drug Sales Market Share by Application (2027-2032) Table 38. Global Poxviridae Infections Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Poxviridae Infections Drug Revenue by Application (2021-2026) & (K Units) Table 40. Global Poxviridae Infections Drug Revenue by Application (2027-2032) & (K Units) Table 41. Global Poxviridae Infections Drug Revenue Market Share by Application (2021-2026) Table 42. Global Poxviridae Infections Drug Revenue Market Share by Application (2027-2032) Table 43. Global Poxviridae Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Poxviridae Infections Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Poxviridae Infections Drug Sales Market Share by Region (2021-2026) Table 46. Global Poxviridae Infections Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Poxviridae Infections Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 50. North America Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 51. Europe Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 53. Europe Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Poxviridae Infections Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Poxviridae Infections Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Poxviridae Infections Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Poxviridae Infections Drug Revenue Market Share by Region (2021-2026) Table 64. Global Poxviridae Infections Drug Revenue Market Share by Region (2027-2032) Table 65. Takeda Pharmaceutical Company Limited Company Information Table 66. Takeda Pharmaceutical Company Limited Business Overview Table 67. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio Table 69. Takeda Pharmaceutical Company Limited Recent Development Table 70. China Biologic Products, Inc. Company Information Table 71. China Biologic Products, Inc. Business Overview Table 72. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio Table 74. China Biologic Products, Inc. Recent Development Table 75. Verrica Pharmaceuticals Inc. Company Information Table 76. Verrica Pharmaceuticals Inc. Business Overview Table 77. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 79. Verrica Pharmaceuticals Inc. Recent Development Table 80. Tonix Pharmaceuticals Holding Corp. Company Information Table 81. Tonix Pharmaceuticals Holding Corp. Business Overview Table 82. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio Table 84. Tonix Pharmaceuticals Holding Corp. Recent Development Table 85. SIGA Technologies, Inc. Company Information Table 86. SIGA Technologies, Inc. Business Overview Table 87. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio Table 89. SIGA Technologies, Inc. Recent Development Table 90. N & N Pharmaceuticals Inc. Company Information Table 91. N & N Pharmaceuticals Inc. Business Overview Table 92. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 94. N & N Pharmaceuticals Inc. Recent Development Table 95. EpiVax, Inc. Company Information Table 96. EpiVax, Inc. Business Overview Table 97. EpiVax, Inc. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. EpiVax, Inc. Poxviridae Infections Drug Product Portfolio Table 99. EpiVax, Inc. Recent Development Table 100. CJ HealthCare Corp. Company Information Table 101. CJ HealthCare Corp. Business Overview Table 102. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio Table 104. CJ HealthCare Corp. Recent Development Table 105. Chimerix, Inc. Company Information Table 106. Chimerix, Inc. Business Overview Table 107. Chimerix, Inc. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Chimerix, Inc. Poxviridae Infections Drug Product Portfolio Table 109. Chimerix, Inc. Recent Development Table 110. CEL-SCI Corporation Company Information Table 111. CEL-SCI Corporation Business Overview Table 112. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio Table 114. CEL-SCI Corporation Recent Development Table 115. BioFactura, Inc. Company Information Table 116. BioFactura, Inc. Business Overview Table 117. BioFactura, Inc. Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. BioFactura, Inc. Poxviridae Infections Drug Product Portfolio Table 119. BioFactura, Inc. Recent Development Table 120. Bavarian Nordic A/S Company Information Table 121. Bavarian Nordic A/S Business Overview Table 122. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio Table 124. Bavarian Nordic A/S Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Poxviridae Infections Drug Distributors List Table 128. Poxviridae Infections Drug Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Poxviridae Infections Drug Product Image Figure 2. Global Poxviridae Infections Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Poxviridae Infections Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Poxviridae Infections Drug Sales (2021-2032) & (K Units) Figure 5. Global Poxviridae Infections Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Poxviridae Infections Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CJ-40011 Image Figure 9. BA-368 Image Figure 10. 24a Image Figure 11. Others Image Figure 12. Global Poxviridae Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Poxviridae Infections Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Poxviridae Infections Drug Sales Market Share by Type (2021-2032) Figure 15. Global Poxviridae Infections Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Poxviridae Infections Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Poxviridae Infections Drug Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Poxviridae Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Poxviridae Infections Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Poxviridae Infections Drug Sales Market Share by Application (2021-2032) Figure 24. Global Poxviridae Infections Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Poxviridae Infections Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Poxviridae Infections Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Poxviridae Infections Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Poxviridae Infections Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Poxviridae Infections Drug Sales Market Share by Country (2021-2032) Figure 41. China Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Poxviridae Infections Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Poxviridae Infections Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Poxviridae Infections Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Poxviridae Infections Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Poxviridae Infections Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Poxviridae Infections Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • CJ-40011
  • BA-368
  • 24a
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceutical Company Limited
  • China Biologic Products, Inc.
  • Verrica Pharmaceuticals Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • SIGA Technologies, Inc.
  • N & N Pharmaceuticals Inc.
  • EpiVax, Inc.
  • CJ HealthCare Corp.
  • Chimerix, Inc.
  • CEL-SCI Corporation
  • BioFactura, Inc.
  • Bavarian Nordic A/S

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Poxviridae Infections Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Poxviridae Infections Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Poxviridae Infections Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Poxviridae Infections Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Poxviridae Infections Drug Market Dynamics
  1. 2.1 Poxviridae Infections Drug Industry Trends
  2. 2.2 Poxviridae Infections Drug Industry Drivers
  3. 2.3 Poxviridae Infections Drug Industry Opportunities and Challenges
  4. 2.4 Poxviridae Infections Drug Industry Restraints
3 Poxviridae Infections Drug Market by Manufacturers
  1. 3.1 Global Poxviridae Infections Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Poxviridae Infections Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Poxviridae Infections Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Poxviridae Infections Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Poxviridae Infections Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Poxviridae Infections Drug Manufacturers, Product Type & Application
  7. 3.7 Global Poxviridae Infections Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Poxviridae Infections Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Poxviridae Infections Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Poxviridae Infections Drug Tier 1, Tier 2, and Tier 3
4 Poxviridae Infections Drug Market by Type
  1. 4.1 Poxviridae Infections Drug Type Introduction
  2. 4.1.1 CJ-40011
  3. 4.1.2 BA-368
  4. 4.1.3 24a
  5. 4.1.4 Others
  6. 4.2 Global Poxviridae Infections Drug Sales by Type
  7. 4.2.1 Global Poxviridae Infections Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Poxviridae Infections Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Poxviridae Infections Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Poxviridae Infections Drug Revenue by Type
  11. 4.3.1 Global Poxviridae Infections Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Poxviridae Infections Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Poxviridae Infections Drug Revenue Market Share by Type (2021-2032)
5 Poxviridae Infections Drug Market by Application
  1. 5.1 Poxviridae Infections Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Poxviridae Infections Drug Sales by Application
  6. 5.2.1 Global Poxviridae Infections Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Poxviridae Infections Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Poxviridae Infections Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Poxviridae Infections Drug Revenue by Application
  10. 5.3.1 Global Poxviridae Infections Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Poxviridae Infections Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Poxviridae Infections Drug Revenue Market Share by Application (2021-2032)
6 Global Poxviridae Infections Drug Sales by Region
  1. 6.1 Global Poxviridae Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Poxviridae Infections Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Poxviridae Infections Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Poxviridae Infections Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Poxviridae Infections Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Poxviridae Infections Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Poxviridae Infections Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Poxviridae Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Poxviridae Infections Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Poxviridae Infections Drug Revenue by Region
  1. 7.1 Global Poxviridae Infections Drug Revenue by Region
  2. 7.1.1 Global Poxviridae Infections Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Poxviridae Infections Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Poxviridae Infections Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Poxviridae Infections Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Poxviridae Infections Drug Revenue (2021-2032)
  8. 7.2.2 North America Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Poxviridae Infections Drug Revenue (2021-2032)
  11. 7.3.2 Europe Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Poxviridae Infections Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Poxviridae Infections Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Poxviridae Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Limited
  2. 8.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 China Biologic Products, Inc.
  8. 8.2.1 China Biologic Products, Inc. Company Information
  9. 8.2.2 China Biologic Products, Inc. Business Overview
  10. 8.2.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio
  12. 8.2.5 China Biologic Products, Inc. Recent Developments
  13. 8.3 Verrica Pharmaceuticals Inc.
  14. 8.3.1 Verrica Pharmaceuticals Inc. Company Information
  15. 8.3.2 Verrica Pharmaceuticals Inc. Business Overview
  16. 8.3.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  18. 8.3.5 Verrica Pharmaceuticals Inc. Recent Developments
  19. 8.4 Tonix Pharmaceuticals Holding Corp.
  20. 8.4.1 Tonix Pharmaceuticals Holding Corp. Company Information
  21. 8.4.2 Tonix Pharmaceuticals Holding Corp. Business Overview
  22. 8.4.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio
  24. 8.4.5 Tonix Pharmaceuticals Holding Corp. Recent Developments
  25. 8.5 SIGA Technologies, Inc.
  26. 8.5.1 SIGA Technologies, Inc. Company Information
  27. 8.5.2 SIGA Technologies, Inc. Business Overview
  28. 8.5.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio
  30. 8.5.5 SIGA Technologies, Inc. Recent Developments
  31. 8.6 N & N Pharmaceuticals Inc.
  32. 8.6.1 N & N Pharmaceuticals Inc. Company Information
  33. 8.6.2 N & N Pharmaceuticals Inc. Business Overview
  34. 8.6.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  36. 8.6.5 N & N Pharmaceuticals Inc. Recent Developments
  37. 8.7 EpiVax, Inc.
  38. 8.7.1 EpiVax, Inc. Company Information
  39. 8.7.2 EpiVax, Inc. Business Overview
  40. 8.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 EpiVax, Inc. Poxviridae Infections Drug Product Portfolio
  42. 8.7.5 EpiVax, Inc. Recent Developments
  43. 8.8 CJ HealthCare Corp.
  44. 8.8.1 CJ HealthCare Corp. Company Information
  45. 8.8.2 CJ HealthCare Corp. Business Overview
  46. 8.8.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio
  48. 8.8.5 CJ HealthCare Corp. Recent Developments
  49. 8.9 Chimerix, Inc.
  50. 8.9.1 Chimerix, Inc. Company Information
  51. 8.9.2 Chimerix, Inc. Business Overview
  52. 8.9.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Chimerix, Inc. Poxviridae Infections Drug Product Portfolio
  54. 8.9.5 Chimerix, Inc. Recent Developments
  55. 8.10 CEL-SCI Corporation
  56. 8.10.1 CEL-SCI Corporation Company Information
  57. 8.10.2 CEL-SCI Corporation Business Overview
  58. 8.10.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio
  60. 8.10.5 CEL-SCI Corporation Recent Developments
  61. 8.11 BioFactura, Inc.
  62. 8.11.1 BioFactura, Inc. Company Information
  63. 8.11.2 BioFactura, Inc. Business Overview
  64. 8.11.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BioFactura, Inc. Poxviridae Infections Drug Product Portfolio
  66. 8.11.5 BioFactura, Inc. Recent Developments
  67. 8.12 Bavarian Nordic A/S
  68. 8.12.1 Bavarian Nordic A/S Company Information
  69. 8.12.2 Bavarian Nordic A/S Business Overview
  70. 8.12.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio
  72. 8.12.5 Bavarian Nordic A/S Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Poxviridae Infections Drug Value Chain Analysis
  2. 9.1.1 Poxviridae Infections Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Poxviridae Infections Drug Production Mode & Process
  6. 9.2 Poxviridae Infections Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Poxviridae Infections Drug Distributors
  9. 9.2.3 Poxviridae Infections Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst